Daratumumab for treating newly diagnosed light chain (AL) amyloidosis

Published on 08 Feb 2023
Last Updated on 08 Feb 2023

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended daratumumab in combination with bortezomib, cyclophosphamide and dexamethasone (DBCd) for inclusion on the MOH List of Subsidised Drugs for treating patients with newly diagnosed light chain (AL) amyloidosis in view of the uncertain extent of clinical benefit and uncertain cost-effectiveness compared with the current treatment option.

Clinical indication, subsidy class and MediShield Life claim limit for daratumumab for AL amyloidosis are provided in the Annex.

Daratumumab for treating newly diagnosed light chain (AL) amyloidosis (Published 8 Feb 2023) [PDF, 126 KB]

PES Daratumumab for treating light chain amyloidosis (Published 8 Feb 2023) [PDF, 120 KB]